Table 13

Dexamethasone safety

Callanan et al44Haller et al59
Number of patients
Ocular adverse events
 IOP elevationDIL: 20% (p<0.001); 1% ≥10 mm HgL: 1.6% ; 0% ≥10 mm Hg
 CataractNRNR
 Anterior chamber cellsNRDDS350: 29.1%; DDS700: 26.4%; C: 1.8%
 Anterior chamber flareNRDDS350: 27.3%; DDS700: 20.8%; C: 8.8%
 Vitreous haemorrhageNRDDS350: 20%; DDS700: 22.6%; C: 5.3%
 Eye painNRDDS350: 18.2%; DDS700: 9.4%; C: 3.5%
 Vitreous disorderNRDDS350: 20%; DDS700: 15.1%; C: 3.5%
 Increased IOPNRDDS350: 14.5%; DDS700: 9.4%; C: 0%
 Conjunctival haemorrhageNRDDS350: 14.5%; DDS700: 7.5%; C: 0%
 Vitreous floatersNRDDS350: 7.3%; DDS700: 17%; C: 0%
No significant differences in: reduced VA, eye irritation, abnormal sensation in eye, macular oedema, eye pruritus, retinal hemorrhage, DR, nonocular events
  • Dil, dexamethasone followed by laser; DDS, dexamethasone; IOP, intraocular pressure; NR, not reported.